Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis
Open Access
- 10 November 2020
- Vol. 70 (9), 1806-1808
- https://doi.org/10.1136/gutjnl-2020-323366
Abstract
No abstract availableKeywords
Funding Information
- Government of Jiangsu Province (Jiangsu Province 333 Project (to GY), Jiangsu Provincial Medical Youth Talent program (Q, Jiangsu Provincial Science Fund for Distinguished)
This publication has 18 references indexed in Scilit:
- Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide StudyGastroenterology, 2021
- Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort StudyGastroenterology, 2020
- Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patientsAnaesthesia, Critical Care & Pain Medicine, 2020
- Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control studyPublished by Cold Spring Harbor Laboratory ,2020
- Involvement of liver in COVID-19: systematic review and meta-analysisGut, 2020
- Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19Published by Cold Spring Harbor Laboratory ,2020
- Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?Journal of Internal Medicine, 2020
- Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case seriesBMJ, 2020
- Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South KoreaPublished by Cold Spring Harbor Laboratory ,2020
- Clinical Characteristics of Coronavirus Disease 2019 in Hainan, ChinaPublished by Cold Spring Harbor Laboratory ,2020